JP2008509673A5 - - Google Patents

Download PDF

Info

Publication number
JP2008509673A5
JP2008509673A5 JP2007525837A JP2007525837A JP2008509673A5 JP 2008509673 A5 JP2008509673 A5 JP 2008509673A5 JP 2007525837 A JP2007525837 A JP 2007525837A JP 2007525837 A JP2007525837 A JP 2007525837A JP 2008509673 A5 JP2008509673 A5 JP 2008509673A5
Authority
JP
Japan
Prior art keywords
sample
marker
expression
patient
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007525837A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008509673A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2005/028781 external-priority patent/WO2006028655A2/en
Publication of JP2008509673A publication Critical patent/JP2008509673A/ja
Publication of JP2008509673A5 publication Critical patent/JP2008509673A5/ja
Pending legal-status Critical Current

Links

JP2007525837A 2004-08-13 2005-08-12 ヒト前立腺癌の同定、評価、予防および治療のための遺伝子、組成物、キットおよび方法 Pending JP2008509673A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60141304P 2004-08-13 2004-08-13
PCT/US2005/028781 WO2006028655A2 (en) 2004-08-13 2005-08-12 Genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of prostate cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2011175448A Division JP2012024089A (ja) 2004-08-13 2011-08-10 ヒト前立腺癌の同定、評価、予防および治療のための遺伝子、組成物、キットおよび方法

Publications (2)

Publication Number Publication Date
JP2008509673A JP2008509673A (ja) 2008-04-03
JP2008509673A5 true JP2008509673A5 (enExample) 2008-09-25

Family

ID=36036805

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2007525837A Pending JP2008509673A (ja) 2004-08-13 2005-08-12 ヒト前立腺癌の同定、評価、予防および治療のための遺伝子、組成物、キットおよび方法
JP2011175448A Pending JP2012024089A (ja) 2004-08-13 2011-08-10 ヒト前立腺癌の同定、評価、予防および治療のための遺伝子、組成物、キットおよび方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2011175448A Pending JP2012024089A (ja) 2004-08-13 2011-08-10 ヒト前立腺癌の同定、評価、予防および治療のための遺伝子、組成物、キットおよび方法

Country Status (7)

Country Link
US (1) US20060068425A1 (enExample)
EP (1) EP1784511A4 (enExample)
JP (2) JP2008509673A (enExample)
KR (1) KR20070052788A (enExample)
CN (2) CN101018874A (enExample)
CA (1) CA2576624A1 (enExample)
WO (1) WO2006028655A2 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002337657A1 (en) * 2001-07-25 2003-02-17 Millennium Pharmaceuticals, Inc. Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of prostate cancer
US7294704B2 (en) 2003-08-15 2007-11-13 Diadexus, Inc. Pro108 antibody compositions and methods of use and use of Pro108 to assess cancer risk
US10066268B2 (en) * 2004-05-07 2018-09-04 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Methods of diagnosing or treating prostate cancer using the ERG gene, alone or in combination with other over or under expressed genes in prostate cancer
CA2622295C (en) 2005-09-12 2019-01-15 The Regents Of The University Of Michigan Recurrent gene fusions in prostate cancer
US9957569B2 (en) * 2005-09-12 2018-05-01 The Regents Of The University Of Michigan Recurrent gene fusions in prostate cancer
CN1903876B (zh) * 2006-07-10 2010-09-01 郑鸿 一种多肽、编码它的核酸分子及用途
CN103233063A (zh) * 2006-11-08 2013-08-07 密歇根大学董事会 前列腺癌标志物spink1及其应用
EP2155897A2 (en) * 2007-03-30 2010-02-24 Source Precision Medicine, Inc. d/b/a Source MDX. Gene expression profiling for identification, monitoring, and treatment of prostate cancer
US9303291B2 (en) 2007-07-06 2016-04-05 The Regents Of The University Of Michigan MIPOL1-ETV1 gene rearrangements
WO2009105335A1 (en) * 2008-02-22 2009-08-27 St.Jude Children's Research Hospital Methods and compositions for the diagnosis and treatment of acute lymphoblastic leukemia
KR101018665B1 (ko) * 2008-08-18 2011-03-04 재단법인서울대학교산학협력재단 전립선암 진단 방법 및 장치
ES2725356T3 (es) 2009-04-29 2019-09-23 Henry M Jackson Found Advancement Military Medicine Inc Anticuerpos monoclonales de ERG2 y su uso terapéutico
BRPI1007704A2 (pt) * 2009-05-12 2019-12-03 Koninklijke Philips Electronics N.V. fosfodiesterase 4d7 (pde4d7), para uso como um marcador para câncer de próstata maligno, sensível a hormônio; composição ou método de aquisição de dados ou imunoensaio para diagnosticar, detectar, monitorar ou prognosticar câncer de prostata maligno, sensível ao hormônio ou para diagnosticar, detectar, monitorar ou prognosticar a progressão para câncer de próstata maligno, sensível a hormônio; uso de pde4d7; imunoensaio para discriminar entre um tumor de próstata benigno e um câncer de próstata maligno, sensível a hormônio; método para identificar um indivíduo para elegibilidade para terapia contra câncer de próstata maligno, sensível a hormônio; imunoensaio para classificar um indivíduo ou corte de indivíduos com uma doença de câncer de próstata maligno, sensível a hormônio; composição farmacêutica inibitória para o tratamento ou prevenção de câncer de próstata maligno, sensível a hormônio; composição farmacêutica estimulatória; e; uso de um anticorpo específico para a proteína pde4d7 e/ou uma variante de anticorpo específica para a proteína pde4d7
US8426133B2 (en) 2009-05-26 2013-04-23 Quest Diagnostics Investments Incorporated Methods for detecting gene dysregulation by intragenic differential expression
US9938582B2 (en) * 2009-09-17 2018-04-10 The Regents Of The University Of Michigan Recurrent gene fusions in prostate cancer
US8546552B2 (en) 2009-12-23 2013-10-01 Quest Diagnostics Investments Incorporated TMPRSS2 for the diagnosis of prostate disease
US20120276552A1 (en) * 2010-01-05 2012-11-01 University Of Cincinnati Serum spla2-iia as diagnosis marker for prostate and lung cancer
CA3081061C (en) 2010-07-27 2023-01-03 Genomic Health, Inc. Method for using expression of klk2 to determine prognosis of prostate cancer
US8945556B2 (en) 2010-11-19 2015-02-03 The Regents Of The University Of Michigan RAF gene fusions
CN103797120B (zh) * 2011-09-16 2017-04-12 上海长海医院 前列腺癌的生物学标志物、治疗靶点及其用途
MX351626B (es) 2012-01-31 2017-10-23 Genomic Health Inc Algoritmo de perfil de expresion genica y prueba para determinar la prognosis de cancer de prostata.
JP5429725B1 (ja) * 2013-03-22 2014-02-26 独立行政法人理化学研究所 前立腺癌の進行度の評価方法、前立腺癌の検出方法、および検査キット
KR20170116009A (ko) * 2014-12-01 2017-10-18 프라운호퍼-게젤샤프트 추어 푀르더룽 데어 안게반텐 포르슝 에.파우. 전립선암의 진단을 위한 신규한 rna-바이오마커 시그니처
JP6815331B2 (ja) * 2015-04-21 2021-01-20 ジェネンテック， インコーポレイテッド 前立腺がんの分析のための組成物及び方法
CN109198732A (zh) * 2018-08-20 2019-01-15 苏州晞光生物科技有限公司 一种智能化可穿戴检测人体分泌物的服装及测试方法
CN117741155A (zh) * 2023-11-21 2024-03-22 中国药科大学 Abcc4蛋白用于制备前列腺癌诊断试剂盒的用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6972170B1 (en) * 1997-12-01 2005-12-06 Sloan-Kettering Institute For Cancer Research Markers for prostate cancer
US6926898B2 (en) * 2000-04-12 2005-08-09 Human Genome Sciences, Inc. Albumin fusion proteins
KR100359941B1 (ko) * 2000-04-14 2002-11-07 엘지전자 주식회사 바이오칩 제조방법
WO2002079238A2 (en) * 2001-04-02 2002-10-10 DeveloGen Aktiengesellschaft für entwicklungsbiologische Forschung Protein disulfide isomerase and abc transporter homologous proteins involved in the regulation of energy homeostasis
EP1468110A4 (en) * 2001-06-10 2008-01-30 Irm Llc MOLECULAR SIGNATURES NORMALLY TO THE DEATH LEADING CARCINOME
AU2002337657A1 (en) * 2001-07-25 2003-02-17 Millennium Pharmaceuticals, Inc. Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of prostate cancer
US20040142325A1 (en) * 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
US6949342B2 (en) * 2001-12-21 2005-09-27 Whitehead Institute For Biomedical Research Prostate cancer diagnosis and outcome prediction by expression analysis
EP2360476B1 (en) * 2002-02-13 2017-10-25 BioMedica Diagnostics Inc. Methods for selecting treatment regimens and predicting outcomes in cancer patients
US20040029151A1 (en) * 2002-04-09 2004-02-12 Affymetrix, Inc. Molecular genetic profiling of gleason grades 3 and 4/5 prostate cancer
DE10234901A1 (de) * 2002-07-26 2004-02-12 Metagen Pharmaceuticals Gmbh Verwendung von am Mrp4 bindenden Substanzen zur Diagnose und Behandlung von Krebserkrankungen

Similar Documents

Publication Publication Date Title
CN102333887B (zh) 用于检测gi癌转移的方法
US20130040852A1 (en) Biomarkers based on a multi-cancer invasion-associated mechanism
CN109890977A (zh) 通过基于生物流体的无细胞dna(cfdna)测定评价器官损伤状态的基于免疫探针的新方法
JP2012526554A5 (enExample)
JP6285009B2 (ja) 前立腺ガンの予後の検知及び判定のための組成物及び該検知及び判定方法
US20140005070A1 (en) Markers associated with cyclin-dependent kinase inhibitors
CA2318354A1 (en) Biomarkers and targets for diagnosis, prognosis and management of prostate disease
JP2012525855A5 (enExample)
JP2013505429A5 (enExample)
CA2882759A1 (en) Detection of the ntrk1-mprip gene fusion for cancer diagnosis
JP2010508855A5 (enExample)
JP2013500001A5 (enExample)
JP2004509643A (ja) アルキル化剤を用いた化学療法による治療に対する臨床反応を予測する方法
JP2020527047A (ja) 大腸癌の診断方法
JP6387001B2 (ja) Ｃｄｋ阻害剤と関連するバイオマーカー
US20220162710A1 (en) Composition for diagnosis or prognosis prediction of glioma, and method for providing information related thereto
JP2008512984A5 (enExample)
IL285031A (en) Diagnosis of inflammatory bowel diseases
JP2009539370A5 (enExample)
DE60325541D1 (de) Verfahren/Präparat zur Erkennung von Pankreaskrebs
WO2011093606A2 (ko) Pna 기반의 실시간 pcr 클램핑을 이용한 braf 돌연변이 검출 방법 및 키트
JP2021503289A (ja) 新規なｃｉｐ２ａバリアント及びその使用
WO2014176047A1 (en) Markers for ezh2 inhibitors
JP2009524051A5 (enExample)
US20130288918A1 (en) Colorectal Cancer Screening Method